Anoro
Author: Chris Mulligan
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
DRUG OVERVIEW
GlaxoSmithKline and Theravance (now Innoviva) developed the once-daily inhaled combination, Anoro, consisting of umeclidinium and vilanterol for the treatment of chronic obstructive pulmonary disease (COPD). Umeclidinium is a long-acting muscarinic antagonist, while vilanterol is a long-acting beta 2 agonist. In December 2013, the US Food and Drug Administration approved Anoro as a maintenance therapy for the treatment of airflow obstruction in patients with COPD. In May 2014, the therapy received marketing authorization in the EU and was later approved in Japan in July 2014.
TABLE OF CONTENTS
4 OVERVIEW
4 Drug Overview
5 Product Profiles
5 Anoro Ellipta : Chronic obstructive pulmonary disease (COPD)
LIST OF FIGURES
12 Figure 1: Anoro for COPD – SWOT analysis
13 Figure 2: Datamonitor Healthcare’s drug assessment summary of Anoro for COPD
14 Figure 3: Datamonitor Healthcare’s drug assessment summary of Anoro for COPD
17 Figure 4: Anoro sales for COPD across the US, Japan, and five major EU markets, by country, 2017–26
LIST OF TABLES
6 Table 1: Anoro drug profile
7 Table 2: Anoro Phase III data in COPD
18 Table 3: Anoro sales for COPD across the US, Japan, and five major EU markets, by country ($m), 2017–26
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Tudorza Pressair 
Sign up to the